Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
11. Tesofensine (NS 2330)[1] Tesofensine---[1] 6 💬
2ACT-293987 (NS-304)----[1] 86 💬
3Active topical NS2 1% dermatologic cream----[1] 160 💬
4BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester[2] Bardoxolone,
Bardoxolone methyl		[2] Bardoxolone ,
Bardoxolone methyl 💬 		--[1] 86 💬
5Ch11-1F4 (NSC-711516)----[1] 28 💬
6Corticosteroid or NSAID----[1] 46 💬
7Ips-nsc cells----[1] 6 💬
8Non-steroidal anti-inflammatory drug (NSAID)----[1] 46 💬
9Non-steroidal anti-inflammatory drugs (NSAIDs)----[1] 107 💬
10Norovirus -specific T-cell (NST) therapy----[1] 65 💬
11NS----[1] 2 💬
12NS 2330----[1] 6 💬
13NS-065/NCNP-01----[1] 113 💬
14NS-089/NCNP-02----[1] 113 💬
15NS-304----[3] 70, 86, 88 💬
16NS-304 Placebo----[2] 70, 88 💬
17NS2----[1] 160 💬
18NS2330----[1] 6 💬
19NSAID----[1] 271 💬
20NSAIDs----[4] 46, 70, 107, 271 💬
21NSAIDs (permitted,not necessary)----[1] 46 💬
22NSAIDs and sulfasalazine[1] Sulfasalazine[1] Sulfasalazine 💬 --[1] 271 💬
23NsNSAIDs----[2] 107, 271 💬
24NSP001----[1] 96 💬
25Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac[1] Etodolac[1] Etodolac 💬 [1] PTGS2 💬 [22] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬[1] 46 💬
26Other Non-selective NSAIDs----[1] 271 💬
27Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses----[1] 46 💬
28Plantain NSP----[1] 96 💬
29Recombinant human heparan Nsulfatase (rhHNS)----[1] 19 💬
30Satralizumab (120 mg/PFS with NSD)[1] Satralizumab[1] Satralizumab 💬 [1] IL6R 💬 [12] Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬[1] 13 💬
31Selexipag, ACT-293987 (NS-304)[1] Selexipag[1] Selexipag 💬 [1] PTGIR 💬 [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬[1] 86 💬